Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release niacin/laropiprant in primary hypercholesterolemia or mixed dyslipidemia
NCT01274559Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2011
- Primary completion
- Feb 2013
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and mixed dyslipidemia comparing Extended-release niacin/laropiprant with Placebo (2 arms). Primary endpoint: Low Density Lipoprotein-Cholesterol at 12 weeks. Started Mar 2011; status: terminated.
02
Drugs
laropiprant + niacin
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01274559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01274559.